

## **APPENDIX 2**

### **Contents**

Standardised review template for initial electronic diabetes review .....	2
Supplementary Table S1: Criteria for escalation to bedside diabetes review in the intervention arm of the STOIC-D Surgery trial.....	4
Supplementary Table S2: Secondary glucometric outcomes in the STOIC-D Surgery trial. ....	5
Supplementary Table S3: Causes of mortality in the STOIC-D Surgery trial. ....	6
Supplementary Table S4: Adverse events in the STOIC-D Surgery trial.....	6

## Standardised review template for initial electronic diabetes review

The text of the review template for the sections including information recorded by the inpatient diabetes team. Formatting applied to the template when displayed in the electronic medical record is not shown. Additional sections displaying information derived directly from the electronic medical record are not shown. Text shown in square brackets is indicative of prompts for specific data entry or drop-down lists of options from which the person completing the template selects. Text shown in braces is indicative of information taken programmatically from the electronic medical record. Three asterisks indicate free text entry by the person completing the template.

-----

Inpatient Diabetes Service (IDS) Electronic Diabetes Review (EDR) - Initial

Review of {patient name}, {age}yo {gender} on {date of review} during encounter {contact serial number}.

Plan for Home Team:

1. Inpatient glucose target: [drop-down menu]
2. Please make these diabetes team referrals: [drop-down menu]
3. Please commence a supplemental insulin scale: [drop-down menu]
4. Please order these investigations: [drop-down menu]
5. Please make these changes to therapy: \*\*\*
6. Current discharge plan: \*\*\*

Diabetes History:

Pre-existing diabetes?: [drop-down menu]

Last HbA1c: \*\*\*% done in \*\*\*.

Year of diagnosis: \*\*\*

Diabetes type: [drop-down menu]

Complications - Macro: [drop-down menu]

Complications - Micro: [drop-down menu]

Complications - Auton.: [drop-down menu]

Complications - Other: [drop-down menu]

Pre-admission Management:

Medical therapy: [drop-down menu]

BG monitoring method: [drop-down menu]

BG monitoring freq.: [drop-down menu]

Taking glucocorticoids?: [drop-down menu]

Care team: [drop-down menu]

Home BG levels: \*\*\*

Other diabetes-relevant issues pre-admission: \*\*\*

Inpatient Management:

On glucocorticoids?: [drop-down menu] \*\*\*

On TPN/EN?: [drop-down menu] \*\*\*

Inpt medical therapy: [drop-down menu]

Inpatient Glucose Management Issues:

-Admitted with \*\*\*

-BGs of \*\*\*

\*\*\*

-----

**Supplementary Table S1: Criteria for escalation to bedside diabetes review in the intervention arm of the STOIC-D Surgery trial.** Data are presented as median (quartile 1 - quartile 3) or number (percentage).

Request from the home team that the participant be reviewed directly by the IDS.
A diabetes diagnosis type that is anything other than type 2 diabetes (T2DM) e.g. type 1 diabetes (T1DM), type 3c diabetes (T3cDM), Latent Autoimmune Diabetes in Adults (LADA).
Commencement of a significant dose of oral glucocorticoids i.e. equal to or greater than prednisolone 5mg total daily dose or equivalent(27).
If on oral glucocorticoids at the time of admission, an increase in dose above the regular outpatient dose.
Commencement of supplemental or replacement therapeutic nutrition i.e. parenteral nutrition or enteral feeds administered via an enteral access tube e.g. nasogastric tube (NGT), percutaneous endoscopic gastrostomy (PEG) tube. This does not include supplemental nutrition that a participant ingests orally e.g. Fortisip® nutritional supplement, regardless of whether this is prescribed by a dietitian.
A major hypoglycaemic event i.e. $BGL \leq 3.0$ mmol/L.
A major hyperglycaemic event i.e. $BGL \geq 20.0$ mmol/L.
Persistent hyperglycaemia i.e. 2 days on which there is any $BGL \geq 15.0$ mmol/L or 3 days on which there is any $BGL \geq 12.0$ mmol/L.
HbA1c $\geq 8.0\%$ .

**Supplementary Table S2: Secondary glucometric outcomes in the STOIC-D Surgery trial.**

	<b>Intervention</b>	<b>Control</b>
PDWMG (mmol/L)	8.7 (7.4-10.2)	8.8 (7.6-10.5)
Mean difference	-0.2 mmol/L (95%CI -0.4 to -0.01)	
PDWMG <12.0 mmol/L	621 (91%)	614 (89%)
AGDs	1.5 ± 2.6	1.4 ± 2.3

Data are presented as median (quartile 1 - quartile 3), number (percentage), or mean ± standard deviation.  
PDWMG = patient-day-weighted mean glucose. AGD = adverse glycaemic day.

**Supplementary Table S3: Causes of mortality in the STOIC-D Surgery trial.** \*Trauma as a cause of mortality includes all patients whose presenting problem was traumatic injury where the patient succumbed from their injuries and mortality was not a consequence of an iatrogenic complication.

	Intervention	Control	Total
Cardiac arrest	1	2	3
Intracranial haemorrhage	2	4	6
Ischaemic gut	1	1	2
Pulmonary embolus	1	-	1
Raised intracranial pressure	1	1	2
Respiratory arrest	-	4	4
Sepsis	2	3	5
Trauma*	8	14	22

**Supplementary Table S4: Adverse events in the STOIC-D Surgery trial.**

	Intervention	Control	p value
Inpatient mortality	16 (2.4%)	29 (4.2%)	0.078
BG <4.0 mmol/L	322 (1.1%)	269 (1.0%)	0.17
BG <3.0 mmol/L	98 (0.3%)	82 (0.3%)	0.49
BG <2.2 mmol/L	59 (0.2%)	48 (0.2%)	0.53

Data are presented as n (%).